IBDEI0EC ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,6597,1,4,0)
 ;;=4^C65.9
 ;;^UTILITY(U,$J,358.3,6597,2)
 ;;=^5001253
 ;;^UTILITY(U,$J,358.3,6598,0)
 ;;=C50.912^^30^396^129
 ;;^UTILITY(U,$J,358.3,6598,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6598,1,3,0)
 ;;=3^Malig Neop Left Female Breast,Unspec Site
 ;;^UTILITY(U,$J,358.3,6598,1,4,0)
 ;;=4^C50.912
 ;;^UTILITY(U,$J,358.3,6598,2)
 ;;=^5001196
 ;;^UTILITY(U,$J,358.3,6599,0)
 ;;=C50.911^^30^396^151
 ;;^UTILITY(U,$J,358.3,6599,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6599,1,3,0)
 ;;=3^Malig Neop Right Female Breast,Unspec Site
 ;;^UTILITY(U,$J,358.3,6599,1,4,0)
 ;;=4^C50.911
 ;;^UTILITY(U,$J,358.3,6599,2)
 ;;=^5001195
 ;;^UTILITY(U,$J,358.3,6600,0)
 ;;=C50.919^^30^396^121
 ;;^UTILITY(U,$J,358.3,6600,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6600,1,3,0)
 ;;=3^Malig Neop Female Breast,Unspec Site
 ;;^UTILITY(U,$J,358.3,6600,1,4,0)
 ;;=4^C50.919
 ;;^UTILITY(U,$J,358.3,6600,2)
 ;;=^5001197
 ;;^UTILITY(U,$J,358.3,6601,0)
 ;;=C62.90^^30^396^159
 ;;^UTILITY(U,$J,358.3,6601,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6601,1,3,0)
 ;;=3^Malig Neop Testis,Unspec
 ;;^UTILITY(U,$J,358.3,6601,1,4,0)
 ;;=4^C62.90
 ;;^UTILITY(U,$J,358.3,6601,2)
 ;;=^5001236
 ;;^UTILITY(U,$J,358.3,6602,0)
 ;;=D03.9^^30^396^161
 ;;^UTILITY(U,$J,358.3,6602,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6602,1,3,0)
 ;;=3^Melanoma in Situ,Unspec
 ;;^UTILITY(U,$J,358.3,6602,1,4,0)
 ;;=4^D03.9
 ;;^UTILITY(U,$J,358.3,6602,2)
 ;;=^5001908
 ;;^UTILITY(U,$J,358.3,6603,0)
 ;;=C45.0^^30^396^162
 ;;^UTILITY(U,$J,358.3,6603,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6603,1,3,0)
 ;;=3^Mesothelioma of Pleura
 ;;^UTILITY(U,$J,358.3,6603,1,4,0)
 ;;=4^C45.0
 ;;^UTILITY(U,$J,358.3,6603,2)
 ;;=^5001095
 ;;^UTILITY(U,$J,358.3,6604,0)
 ;;=C90.01^^30^396^164
 ;;^UTILITY(U,$J,358.3,6604,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6604,1,3,0)
 ;;=3^Multiple Myeloma,In Remission
 ;;^UTILITY(U,$J,358.3,6604,1,4,0)
 ;;=4^C90.01
 ;;^UTILITY(U,$J,358.3,6604,2)
 ;;=^267515
 ;;^UTILITY(U,$J,358.3,6605,0)
 ;;=C90.00^^30^396^165
 ;;^UTILITY(U,$J,358.3,6605,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6605,1,3,0)
 ;;=3^Multiple Myeloma,Not in Remission
 ;;^UTILITY(U,$J,358.3,6605,1,4,0)
 ;;=4^C90.00
 ;;^UTILITY(U,$J,358.3,6605,2)
 ;;=^5001752
 ;;^UTILITY(U,$J,358.3,6606,0)
 ;;=C94.6^^30^396^166
 ;;^UTILITY(U,$J,358.3,6606,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6606,1,3,0)
 ;;=3^Myelodysplastic Disease NEC
 ;;^UTILITY(U,$J,358.3,6606,1,4,0)
 ;;=4^C94.6
 ;;^UTILITY(U,$J,358.3,6606,2)
 ;;=^5001846
 ;;^UTILITY(U,$J,358.3,6607,0)
 ;;=D61.82^^30^396^167
 ;;^UTILITY(U,$J,358.3,6607,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6607,1,3,0)
 ;;=3^Myelophthisis
 ;;^UTILITY(U,$J,358.3,6607,1,4,0)
 ;;=4^D61.82
 ;;^UTILITY(U,$J,358.3,6607,2)
 ;;=^334037
 ;;^UTILITY(U,$J,358.3,6608,0)
 ;;=D47.9^^30^396^168
 ;;^UTILITY(U,$J,358.3,6608,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6608,1,3,0)
 ;;=3^Neop Lymphoid,Hematopoietic & Related Tissue,Uncertain Behavior
 ;;^UTILITY(U,$J,358.3,6608,1,4,0)
 ;;=4^D47.9
 ;;^UTILITY(U,$J,358.3,6608,2)
 ;;=^5002260
 ;;^UTILITY(U,$J,358.3,6609,0)
 ;;=D53.9^^30^396^172
 ;;^UTILITY(U,$J,358.3,6609,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6609,1,3,0)
 ;;=3^Nutritional Anemia,Unspec
 ;;^UTILITY(U,$J,358.3,6609,1,4,0)
 ;;=4^D53.9
 ;;^UTILITY(U,$J,358.3,6609,2)
 ;;=^5002298
 ;;^UTILITY(U,$J,358.3,6610,0)
 ;;=D47.4^^30^396^173
 ;;^UTILITY(U,$J,358.3,6610,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6610,1,3,0)
 ;;=3^Osteomyelofibrosis
 ;;^UTILITY(U,$J,358.3,6610,1,4,0)
 ;;=4^D47.4
 ;;^UTILITY(U,$J,358.3,6610,2)
 ;;=^5002259
